Risk of Kidney Stone Formation with Vitamin C Supplementation
Vitamin C supplementation at doses ≥1000 mg/day significantly increases the risk of calcium oxalate kidney stones, particularly in men, by raising urinary oxalate excretion by 20-40%.
Key Evidence from FDA Drug Labeling
The FDA label for ascorbic acid explicitly warns that acute and chronic oxalate nephropathy have been reported with prolonged administration of high doses of ascorbic acid 1. The mechanism is clear: ascorbic acid is metabolically converted to oxalate, and acidification of urine by vitamin C causes precipitation of oxalate stones 1.
Dose-Dependent Risk Profile
High-Risk Doses (≥1000 mg/day)
- Men taking 1000-1499 mg/day have a 12% increased risk of stone formation (OR=1.12,95% CI: 1.11-1.13) 2
- Men taking ≥1000 mg/day have a 41% increased risk compared to those taking <90 mg/day (RR=1.41,95% CI: 1.11-1.80) 3
- Urinary oxalate increases by 20% in non-stone formers and 33% in stone formers at 2000 mg/day 4
Moderate Doses (250-999 mg/day)
- Men taking 250-499 mg/day show a 14% increased risk (OR=1.14,95% CI: 1.00-1.28) 2
- Doses of 500-999 mg/day show borderline significance 2
Women vs. Men
Women do not show significantly increased stone risk at any supplementation dose (250-1500+ mg/day), with odds ratios consistently around 1.0 2. This sex difference is clinically important but mechanistically unexplained.
Mechanism and Metabolic Impact
Vitamin C supplementation increases stone risk through two pathways:
Endogenous oxalate synthesis: A major metabolic route converts ascorbic acid to oxalate via dehydroascorbic acid 1. In responders (40% of individuals), this increases endogenous oxalate production by 39% (544 vs. 391 μmol/day) 5
Enhanced oxalate absorption: Vitamin C increases the percentage of dietary oxalate absorbed from the gut by 31% (10.5% vs. 8.0%) 5
The combined effect raises the Tiselius Risk Index for calcium oxalate stones by 45% (1.10 vs. 0.76) in responders 5.
High-Risk Populations Requiring Caution
The FDA specifically identifies patients at increased risk for oxalate nephropathy 1:
- History of kidney stones (especially calcium oxalate)
- Renal impairment or chronic kidney disease
- Elderly patients (age-related decreased GFR)
- Pediatric patients <2 years (immature kidneys)
- Patients with glucose-6-phosphate dehydrogenase deficiency (separate hemolysis risk)
Clinical Recommendations
For Stone Formers
Limit vitamin C intake to <1000 mg/day, ideally staying at or below the RDA of 90 mg/day for men and 75 mg/day for women 4, 3. The AUA guideline emphasizes reducing dietary oxalate in patients with calcium oxalate stones and relatively high urinary oxalate 6.
For General Population
While the FDA-approved upper limit is 2000 mg/day 5, this does not account for individual stone risk. Men considering supplementation >1000 mg/day should be counseled about increased stone risk, particularly if they have additional risk factors.
Monitoring
If high-dose vitamin C is deemed necessary:
- Obtain baseline 24-hour urine collection measuring oxalate, calcium, citrate, and volume 6
- Monitor renal function in high-risk patients 1
- Ensure adequate hydration to achieve urine volume ≥2.5 L/day 6
Important Caveats
"Responder" phenomenon: Approximately 40% of individuals (both stone formers and non-stone formers) show marked increases in urinary oxalate with supplementation, while others do not 5. This cannot be predicted without metabolic testing.
COVID-19 pandemic effect: Online interest in vitamin C increased four-fold during COVID-19, with sustained elevation and no discussion of stone risk in popular search results 7. This represents an ongoing public health concern.
Dietary vs. supplemental calcium: While vitamin C increases oxalate, maintaining normal dietary calcium (1000-1200 mg/day) is protective as it binds oxalate in the gut, reducing absorption 6.
The evidence consistently demonstrates that vitamin C supplementation at commonly used doses (≥1000 mg/day) poses a real and quantifiable risk for calcium oxalate stone formation, particularly in men. This risk should be weighed against any purported benefits of supplementation, especially given the lack of evidence for vitamin C in preventing or treating most conditions for which it is commonly used 7.